Caredx launches two expanded indications for allosure testing services

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that allosure® is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (spk) transplant. both indicatio.
CDNA Ratings Summary
CDNA Quant Ranking